Jafron Biomedical Hits Day Low at CNY 17.40 Amid Price Pressure

Jafron Biomedical Co., a large-cap player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline today, with its stock price dropping by 3.89% on March 23, 2026. The stock reached an intraday low of CNY 17.40, reflecting ongoing challenges in its financial performance. Over the past week, Jafron's stock has decreased by 7.24%, and its monthly performance shows a decline of 11.37%. Year-to-date, the stock has fallen by 10.83%, significantly underperforming the China Shanghai Composite, which has seen a decline of 3.92% during the same period. The company's one-year performance is particularly concerning, with a drop of 32.67%, contrasting sharply with the 13.33% gain of the broader index. Financial metrics indicate a troubling trend, with net sales plummeting by 39.78% and a pre-tax profit of CNY 80.78 million, down 73.06%. The company's operating cash flow has also reached a low of CNY 779.01 million. Despite a return on equity of 20.51%, Jafron's valuation appears high with a price-to-book ratio of 5.63, raising questions about its long-term growth prospects.